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ABSTRACT
Objective To examine the protective efficacy of measles
vaccination in infants in a low income country before
9 months of age.
Design Randomised clinical trial.
Participants 1333 infants aged 4.5 months: 441 in
treatment group and 892 in control group.
Setting Urban area in Guinea-Bissau.
Intervention Measles vaccination using standard titre
Edmonston-Zagreb vaccine at 4.5 months of age.
MainoutcomemeasuresVaccineefficacyagainstmeasles
infection,admissiontohospitalformeasles,andmeasles
mortality beforestandard vaccinationat 9 months of age.
Results 28% of the children tested at 4.5 months of age
had protective levels of maternal antibodies against
measles at enrolment. After early vaccination against
measles92%hadmeaslesantibodiesat9monthsofage.
A measles outbreak offered a unique situation for testing
the efficacy of early measles vaccination. During the
outbreak, 96 children developed measles; 19% of
unvaccinated children had measles before 9 months of
age. The monthly incidence of measles among the 441
children enrolled in the treatment arm was 0.7% and
amongthe892enrolledinthecontrolarmwas3.1%.Early
vaccination with the Edmonston-Zagreb measles vaccine
prevented infection; vaccine efficacy for children with
serologically confirmed measles and definite clinical
measleswas94%(95%confidenceinterval77%to99%),
foradmissionstohospitalformeasleswas100%(46%to
100%), and for measles mortality was 100% (−42% to
100%).Thenumberneededtotreattopreventonecaseof
measles between ages 4.5 months and 9 months during
the epidemic was 7.2 (6.8 to 9.2). The treatment group
tendedtohaveloweroverallmortality(mortalityrateratio
0.18, 0.02 to 1.36) although this was not significant.
Conclusions In low income countries, maternal antibody
levels against measles may be low and severe outbreaks
of measles can occur in infants before the recommended
ageofvaccinationat9months.Outbreaksofmeaslesmay
becurtailedbymeaslesvaccinationusingtheEdmonston-
Zagreb vaccine as early as 4.5 months of age.
Trial registration Clinical Trials NCT00168558
[ClinicalTrials.gov].
INTRODUCTION
The World Health Organization’s policy for measles
vaccination was established in the early 1980s after
studiesofantibodyresponsestovaccinationatdifferent
ages.
12 The assumption was that children with anti-
bodies were fully protected and those without measur-
able antibodies were fully susceptible and that
vaccination at either 8 or 9 months of age would
provide a similar proportion of protected children. It
was thought, however, that vaccination at 8 months
would lead to more children getting measles after
vaccination, so called vaccine failures. Because it was
believed that vaccine failures would lead to lack of
confidenceinthevaccinationprogramme,vaccination
at 9 months of age was finally recommended and
became global policy. The policy makers did not take
into consideration that by vaccinating earlier, measles
infection would move to an older age group with a
lower case fatality,
3 that vaccinated children have
partial immunityand milder disease,
4 and that vaccine
failureswithmilder diseasedonotdiscouragemothers
from vaccination, rather the opposite.
4 No trial was
done to establish the evidence that by vaccinating at 6,
7,8,or9monthsofagetheeffectsonmeaslesmorbidity
and overall mortality might differ.
3
Thecurrentmeaslesvaccinationpolicywasbasedon
children born to naturally infected mothers. Such
children may not lose protection from maternal
antibodies until around 7 to 9 months of age.
56 The
situation has changed since the 1980s. Most low
income countries have had measles vaccination
programmes for the past 20-25 years. Guinea-Bissau
carried out the first campaign in 1979.
7 As a
consequence many mothers have been immunised
andhavenothadnaturalmeaslesinfection.InGuinea-
Bissau and Senegal we examined the transfer of
maternalantibodiesfrommotherswithknownmeasles
vaccination or natural measles infection. In both sites
immunised mothers transferred only around half the
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drenlostprotectivelevelsearly(unpublisheddata).
89A
new group of children born to immunised mothers
therefore exists who may lose protection by 3 to
5 months of age. This situation should lead to
reconsideration of the policy for measles vaccination.
In a search for a better policy we originally hoped
that measles vaccination using high titre Edmonston-
Zagreb vaccine at 6 months of age could solve the
problemofmeaslescontrolandimprovethesurvivalof
children.
1011Becausethisvaccinewaswithdrawn,
12we
examined two dose strategies that provided the first
dose before 9 months of age.
1213 Two dose strategies
increase the likelihood of getting at least one dose and
thereby increase individual protection and herd
immunity.
14 Vaccination before 9 months of age
should also protect young infants, who have a
particularly high case fatality rate,
15 and might extend
the non-specific beneficial effects of measles vaccina-
tion by providing vaccine to a younger age group.
16-18
Sincethelate1990sspectacularsuccessesinmeasles
control have been obtained with supplemental immu-
nisation activities, including mass campaigns targeting
children aged 9 months to 14 years.
19-21 After such
campaigns in Latin America the age of routine
vaccination has been increased to 12 months as
vaccination at this age is believed to provide fuller
protection
20 and because the risk of exposure to
measles virus is greatly reduced after supplemental
immunisation activities. The success of the campaigns
in Latin America
1920 provides some support for this
strategy. The optimal strategy in Africa may be
different, however, because there are more births per
woman, more urban crowding, a higher risk of early
measlesinfectionbeforethecurrentageofvaccination,
and less continuity in vaccination efforts. Even if
currenteffortsforeliminationaresuccessfulinAfrica,
21
it is likely that break-downs in vaccinations, political
upheaval, and humanitarian crises
22 will cause local
outbreaks. In such situations vaccination against
measles before 9 months of age may be desirable.
Furthermore, delaying the age of vaccination would
reduce the non-specific beneficial effects of the
vaccine.
1617
We have continued to examine possible modifica-
tions in the measles vaccination policy. In 2003 we
started a trial of two doses of Edmonston-Zagreb
measles vaccine at 4.5 and 9 months of age in urban
Guinea-Bissau. We included only children who had
received the third dose of diphtheria, tetanus, and
pertussis vaccine before enrolment. Measles was
present in Guinea-Bissau and shortly after the trial
started an outbreak occurred in the study area and
provided a unique situation for testing the efficacy of
vaccination before 9 months of age.
METHODS
ThetrialwascarriedoutinthestudyareaoftheBandim
Health Project, which covers five districts totalling
about 90000 inhabitants, 30% of the population of the
capitalBissau.
23Thelargestoftheareas,Bandim1,has
been followed since 1978; Bandim 2 and Belem were
includedinthesurveillancesystemin1983,Mindarain
1993, and Cuntum in 1998. The residents have an
identification number in the census files, along with
informationonhousenumberandsocioeconomicand
demographic factors. The houses are visited every
month to register new pregnancies and births. All
children are visited at home every three months until
age 3 years; at these visits we collect information on
breastfeedingstatus,infections,admissionstohospital,
vaccination status, whether the mother lives with the
child, and ownership of pigs, since these factors have
been associated with survival or mortality in children.
The project area has three health centres.
The women of Bissau travel often to visit relatives
livinginotherpartsofthecountryandtotakepartinthe
cashew harvest. About 20% of the mothers are
travelling at any given time. A large proportion of the
childrenthereforemaycomelate forvaccinations.Itis
always possible to obtain information on survival,
however, because if a child dies in the rural areas, the
family in Bissau are informed immediately.
Objectives, study design, and outcomes
The present trial was originally planned to compare
different vaccination strategies using the two main
strains of measles vaccine, Edmonston-Zagreb and
Schwarz, which are used interchangeably in low
income countries. The trial design included three
arms: two dose measles vaccination with Edmonston-
Zagreb vaccine at 4.5 and 9 months of age, Schwarz
vaccine at 9 months of age, and Edmonston-Zagreb
vaccineat9monthsofage.Theprimaryendpointwas
Infants excluded (n=121):
  Previous measles (n=33)
  Recruited within 25 days of three
    dose diphtheria, tetanus, and
    pertussis vaccine (n=88)
Infants excluded (n=70):
  Previous measles (n=25)
  Recruited within 25 days of three
    dose diphtheria, tetanus, and
    pertussis vaccine (n=45)
Two cases within 21 days
Reported measles cases (n=8):
  2 cases tested of whom 2 were
  serologically confirmed, 0 admitted to
  hospital for measles, 0 measles
  mortality
Nine cases within 21 days
Reported measles cases (n=77):
  66 cases tested of whom 60 were
  serologically confirmed, 14 admitted to
  hospital for measles, 7 measles
  mortality
Infants who received three dose diphtheria, tetanus, and pertussis
vaccine and were randomised at local health centres (n=1524)
Edmonston-Zagreb or Schwarz vaccine
at age 9 months (control group)
randomised at age 4.5 months (n=1013)
Edmonston-Zagreb vaccine
(treatment group) randomised
at age 4.5 months (n=511)
Allocation
Followed-up and analysed (n=892) Followed-up and analysed (n=441) Follow-up
Outcomes
Still living in study area (n=422)
Moved (n=18)
Died (n=1)
Still living in study area (n=833)
Moved (n=47)
Died (n=12)
End of study:
9 months
vaccination or
1 June 2004
Exclusions
Fig1 | Flowofchildrenthroughtrial.Numbersofchildrenwithmeaslesarenotmutuallyexclusive
categories but represent different degrees of diagnostic certainty (serologically confirmed) or
clinical severity (admission to hospital, death)
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4.5 months of age and randomised to one of the three
groups. At 9 months of age the children were invited
backtothe healthcentre;the treatmentarmreceiveda
second standard dose of Edmonston-Zagreb vaccine
andthecontrolarmsreceivedastandarddoseofeither
Schwarz vaccine or Edmonston-Zagreb vaccine.
Several studies have suggested that diphtheria,
tetanus, and pertussis given simultaneously with
measles vaccine or after measles vaccination may be
associatedwithincreasedmortalitycomparedwiththe
measles vaccine given alone.
1824-26 For example, in the
high titre measles vaccination trials the excess mortal-
ityingirlsmayhavebeenduetothediphtheria,tetanus,
and pertussis vaccine being given after the measles
vaccine.
9 We made it a condition that children in the
present trial should have received three doses of the
diphtheria, tetanus, and pertussis vaccine before
enrolment. Allowing for an interval of four weeks
between the three dose schedule and measles vaccina-
tion, 4.5 months of age was the earliest we could give
the measles vaccine.
The primary outcomes were survival at 3 years of
age,levelsofmeaslesantibodiesat24monthsofageto
assess likely protection against measles infection, and
protection against measles infection. The trial was
started in August 2003 and follow-up is still ongoing.
Weexpecttoreportlaterthedataonmeaslesantibody
levels and survival. We are currently in add-on studies
assessing the cytokine response after early measles
vaccination and the response to a booster vaccination
at 3 years of age to predict the likely long term efficacy
of early measles vaccination.
Sample size
The sample size was based on the calculation that to
detecta25%differenceinmortalitybetweenanyofthe
groupsweneededtoenrol5755childrenandtofollow
them to 3 years of age. For the evaluation of antibody
levels we calculated that we needed 400 children to
detect a 10% difference in the proportion of those
showing no seroconversion. No sample size was
calculated for protection against measles infection.
We have maintained measles surveillance for the past
25yearsinpartofthestudyareaandwedidnotexpect
sufficientnumbersofmeaslescasestoassesstheimpact
of the various strategies on the incidence of natural
measles infection.
Interim analysis
Contrary to expectations a large outbreak of measles
occurred between November 2003 and May 2004,
shortly after we started the trial. Given the noticeable
efficacy of early measles vaccination one of the
participating ethical committees questioned the ethics
of continuing the trial. The investigators decided after
consultation with the trial data safety monitor (Robin
Bailey) and the ethics committees that the study could
continue because of the limited possibilitiesfor further
outbreaks of measles. Should a new outbreak occur
after the interim analysis, the main study would be
stopped temporarily and all unvaccinated children be
offered the Edmonston-Zagreb measles vaccine at 4.
5 months of age.
Itwasalsodecidedtoreportimmediatelytheefficacy
of early measles vaccination. In contrast to the three
groups specified in the protocol, this interim analysis
woulddirectlycomparetwogroups:childrenreceiving
the Edmonston-Zagreb vaccine at 4.5 months of age
and the combined group of children to receive the
Schwarz vaccine or Edmonston-Zagreb vaccine at
9 months of age. Whereas overall mortality until
3years ofagewasthe primaryoutcomein the planned
trial, the incidence of measles, admissions to hospital
for measles, and measles mortality were the primary
outcomes in the interim analysis. Hence the interim
study reports the efficacy of early vaccination with the
Edmonston-Zagreb vaccine in an outbreak situation.
The study includes all children enrolled in the trial
betweenthestartofthestudyandtheendofMay2004,
when the measles epidemic ended. The present
analysis (fig 1) deals with the effect of Edmonston-
Zagreb measles vaccination only before the 9 month
vaccination; follow-up was censored if the children
received measles vaccine, moved, died, or were at the
endoftheepidemic(1June2004).Theoriginalsample
sizecalculationwasnotrelevanttotheinterimanalysis
butthestudyprocedureswerethesameinthesubgroup
included in the interim analysis.
Enrolment
Newborn infants were identified through the Bandim
HealthProject’sregistrationsystem.Tomakesurethat
study children had received the third dose of
diphtheria, tetanus, and pertussis four weeks before
inclusionwe contactedthe mothers ofchildrenaged6,
10,and14weeksandremindedthemtogotooneofthe
health centres to have their children vaccinated and
giventheoralpoliovaccine.Childrenwereenrolledat
4.5monthsold.Inthemorningafieldworkercontacted
themothersorguardiansofeligiblechildren,explained
the study, filled in a questionnaire on background
factors, and obtained verbal consent. Mothers were
asked to bring their children to the health centre in the
afternoon.
In the afternoon a doctor provided the mothers or
guardians of children presenting at the health centre
with an oral and a written explanation of the study. At
each visit to the health centre the children were
examined by the doctor. Clinical examination and
treatment was independent of randomisation group.
The children received treatment according to local
standards. Children who were sick and needed to be
admittedtohospitalcouldonlyparticipateinthestudy
when they had recovered.
Randomisation and intervention
The data manager, who was not involved in the
recruitmentofchildren,preparedbagswith24numbered
envelopes indicating the randomisation group. These
numbers could not be seen by the doctor informing and
obtaining consent from the mothers or guardians.
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guardians were asked to select one of the envelopes.
This procedure has been used in several other trials in
the studyarea andemphasisestomothersthattheyare
participating in a randomised trial. The children were
randomisedtooneofthreeequallysizedgroups,using
blockrandomisationwith24envelopesperbag.Anew
bag was opened only when the previous one was
empty.
Children randomised to Zagreb-Edmonston vacci-
nation at 4.5 months of age received a standard titre
from the Serum Institute of India, Pune, India (batch
number 2360).
Masking
No placebo was given. Ethical committees in Africa
have been reluctant to use a placebo injection in
vaccine trials,
27 usually preferring some potentially
beneficial vaccination (for example, rabies or menin-
gococcal vaccine), but irrelevant to the main outcome
ofthetrial.Wehaveusedinactivatedpoliovaccineasa
control vaccine in previous trials of early measles
vaccination.
18 As reported recently, however, such a
vaccine may have an impact on the female to male
mortalityratio.
18Itwasthereforepreferablenottohave
anotheractive controlvaccine.Furthermore,if wehad
used a placebo some mothers in the control group
might erroneously have believed that the child had
receivedameaslesvaccinedespiteitnotbeingnotedon
the vaccination card. As long as participants remained
inthestudyareathismatteredlittleastheywouldallbe
called systematically for measles vaccination at
9monthsofage.Iftheymovedfromthearea,however,
they might not have gone to a health centre to seek
measlesvaccination.Mothersofchildreninthecontrol
group were told that their children would not receive
measles vaccine at enrolment but that they should be
vaccinated at 9 months of age.
Outcomes
Maternal antibody levels and seroconversion after early
vaccination
We collected blood samples to assess the levels of
maternal antibody levels against the measles virus and
antibody levels after different measles vaccination
strategies. We collected samples at 4.5, 9, and
24 months of age from the early vaccination group
and at 9, 18, and 24 months of age from the control
groups. Some of these samples were collected from
children during the measles epidemic (see table on
bmj.com). These samples have been used to indicate
the level of maternal antibodies at 4.5 and 9 months of
agewithinthiscohort.Furthermore,thesamplesat4.5
and 9 months of age in the treatment group have been
used to document the degree of seroconversion after
early measles vaccination. We excluded children who
had measles before sampling or who had known
exposure to measles at home.
Measles surveillance
Ameaslesoutbreakbuiltupduringtheautumnof2003
and lasted until May 2004. During that time the
Bandim Health Project offered free consultations and
treatment for children with measles, both at the
project’s premises and at the paediatric ward in the
nationalhospital,Bissau.Childrenwithmeaslesseenat
the local health centres in the study area were
identified. Those children identified were visited at
hometo offer treatmentand toidentify new cases.The
houses were visited by fieldworkers as part of their
routine activities to identify new pregnancies and to
followchildrenunder 3years.Fieldworkersattempted
to identify additional cases of measles at these visits.
Several special activities for data collection were
started during the outbreak. Children under 5 years
werevisitedinMarchorApril2004afterthepeakofthe
outbreak to obtain information on measles cases. Two
special surveys to obtain information on measles
infectionorexposuretomeaslesinfectionwerecarried
outforchildrenenrolledinthepresenttrial,intheearly
phaseinJanuary2004andattheendoftheoutbreak,in
June or July 2004. These surveys were carried out by
fieldworkers who were not involved in the enrolment
of children. At enrolment and at vaccination at nine
months mothers or guardians were asked whether the
children had had measles. Children not previously
identified with measles were visited at home by a
Table 1 |CharacteristicsofchildrenallocatedtoEdmonston-Zagrebmeaslesvaccineatage4.
5months(treatment)ortoSchwarzorEdmonston-Zagrebvaccineatage9months(controls).
Valuesarepercentages(numbers)unlessstatedotherwise
Characteristic Treatment arm Control arm
No of children 441 892
Median age (months) at enrolment (25-75%
centiles)
4.8 (4.7-5.2) 4.8 (4.7-5.1)
Median age (years) of mother (25-75% centiles) 25 (21-29) 25 (20-29)
Resident of Bandim district 41 (182) 45 (398)
Boys 48 (211) 50 (442)
Twins 3 (15) 3 (22)
Pepel ethnic group 30 (111) 28 (210)
Risk factors at enrolment (age 4.5 months):
Not being breast fed 2 (8) 3 (25)
Pigs in household 16 (71) 13 (119)
Pigs in house 32 (141) 29 (261)
Average No of people per bed 3.0 3.0
No of people per bedroom 4.2 4.3
Inside toilet 16 (72) 14 (127)
Electricity 42 (184) 42 (378)
Functioning electricity 26 (113) 25 (222)
Morbidity and anthropometry:
Admission to hospital before age 4.5 months 1 (5) 1(5)
Fever 10 (46) 11 (101)
Diarrhoea 5 (22) 5 (46)
Mean respiratory rate 42 43
BCG scar 82 (362) 82 (728)
Chloroquine at home 29 (129) 27 (236)
Mean (SD) weight (g) 7109 (956) 7140 (979)
Mean (SD) arm circumference (mm) 140 (11) 141 (12)
Mean (SD) height (cm) 64.1 (2.9) 64.4 (2.8)
Mean (SD) mother’s arm circumference (mm) 270 (34) 270 (33)
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Measles diagnosis
We used both clinical and serological criteria to define
thediagnosticqualityofchildrenreportedwithmeasles
duringtheoutbreak.Childrenexaminedbytheproject
doctors or at the paediatric ward were considered to
havedefiniteclinicalmeaslesiftheyhadKoplik’sspots
oratypicalmeaslesrash,orboth,orahistoryofmeasles
with typical desquamation simultaneous with less
specific symptoms of infection, including fever,
cough, respiratory infection, stomatitis, or conjuncti-
vitis. Children reported as having measles but who
were not seen in the acute phase were visited at home
by a doctor and were considered to have probable
measles if the family reported symptoms of rash,
desquamation, cough, and conjunctivitis, and contacts
with known children with measles infection. We
included both definite and probable cases of measles
in the analysis of measles incidence.
We collected blood samples from children in the
acute phase of measles and one month later for
determination of antibody levels. For children seen
only in the second month after measles infection a
blood sample was collected for possible confirmation
with an IgM antibody test.
Morethan1750casesofmeasleswerereportedinthe
studyareain2003-4.Duringthemostintensivemonths
of the outbreak, from December 2003 to March 2004,
the three study doctors were overwhelmed by the
management of cases at the project and health centres.
For this reason many cases not seeking care were not
seen in the acute phase but identified later through our
surveillancesystems.Childrenbroughttotheprojector
health centres were therefore more likely to have a
diagnosis of definite clinical measles than children
identifiedthroughthecommunity’sregistrationsystem.
Admission to hospital for measles
TheBandimHealthProjectregisterschildrenadmitted
to the national hospital in Bissau, which has the only
paediatric ward in the country. Overall, 905 children
withmeasleswereadmittedtohospitalfromthecityof
Bissauduring the outbreak.From the vaccination card
we obtained sufficient information to identify the
children in the project’s main registration system.
2829
Measles mortality
Children with measles were followed to ascertain
deathsintheacutephase—definedaswithinonemonth
(31 days) of the onset of rash.
Concealment of vaccination status and identification of
measles cases
The fieldworkers carrying out the surveys on measles
infection or exposure to measles in the study popula-
tion were unaware of the vaccination status of the
children and had not taken part in enrolment. The
doctor carrying out the clinical examination of
suspected cases was asked to avoid looking at the
vaccination card before making a diagnosis. At the
paediatric ward, the doctors admitting the children
would not look at the vaccination card and ascertain-
ment may therefore have been relatively blind at the
hospital.
Testing for measles antibodies
The Medical Research Council Laboratories in the
Gambia carried out IgM and IgG testing for measles
antibodiesaspreviously described.
30Thesensitivityof
the IgG measles haemagglutination inhibition assay is
15.6 mIU, the minimum detectable level is 31.2 mIU,
andtheprotectivelevelisconsideredtobe125mIUor
greater.
31 A fourfold increase in IgG titre or a positive
IgMtestresultwasinterpretedasconfirmationofacute
measles infection. Because of the decline in the IgM
response in the second month after measles infection,
we did not interpret negative IgM responses in
convalescent sera as invalidating a measles diagnosis.
OnlynegativeIgGresponsesinconvalescentserawere
considered to invalidate a measles diagnosis.
Statistical analyses and vaccine efficacy
Many children had had measles before enrolment. As
they were not susceptible to the intervention we
excluded such children from the present analysis
(fig 1). Children with measles soon after enrolment
were likely to have contracted infection before enrol-
ment, and vaccination would not necessarily have
prevented infection in the context of intensive expo-
suretomeaslesvirus.Thusweexcludedfromthemain
analysischildrenwithmeaslesoccurringwithin21days
of enrolment. Likewise, we followed up children to
21daysafterthemeaslesvaccinationat9monthsofage
as this vaccination is unlikely to have prevented
infection within that period. We calculated vaccine
efficacy against measles infection, admissions to
hospital for measles, and measles mortality from the
incidence rate ratio between treated and control
children using the formula: vaccine efficacy=(1−inci-
dence rate ratio)×100.
32 We estimated the incidence
rateratiousingaCoxproportionalhazardsmodel,with
time since enrolment as the time variable.
The protocol specified that children should be
enrolled four weeks after the three dose vaccination
schedule against diphtheria, tetanus, and pertussis. In
the first month, however, a programming error meant
that 133 children were enrolled shortly after receiving
the three dose schedule. In the main analysis we
censoredchildrenwhowereenrolledwithin25daysof
the three dose vaccination. Results are also presented
with inclusion of these children.
RESULTS
Between August 2003 and May 2004 1524 children
were enrolled in the study; 133 were recruited within
25 days of the three dose diphtheria, tetanus, and
pertussis vaccination schedule and were therefore not
included in the main analysis (fig 1). Among the
remaining 1391 children, 58 had been seen with
measles or reported measles before enrolment and
RESEARCH
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1333 children were included in the analysis of the
protective effect of early measles vaccination using the
Edmonston-Zagrebvaccine;441inthegrouptreatedat
4.5 months (treatment group) and 892 in the two
control groups due to receive the first dose of measles
vaccine at 9 months of age.
Baseline data
Children in the treatment and control arms were
similar for demographic, socioeconomic, and health
relatedfactors(table 1).Themediandelaybetweenthe
three dose diphtheria, tetanus, and pertussis vaccina-
tion and enrolment was 32 days (25-75% centiles 29-
35). The median age at enrolment was 4.8 months (25-
75%centiles4.7-5.1);871(65.3%)wereaged4months,
427 (32.0%) 5 months, and 35 (2.6%) 6 months. Of the
188 children in the treatment arm tested for maternal
antibodies at enrolment (see table on bmj.com), 61%
(n=114)had detectable levelsbut only 28%(n=52)had
protective levels, the prevalence being lower among
girls than among boys (20% v 35%; relative risk 0.55,
95% confidence interval 0.34 to 0.91). At 9 months of
age, only 5% (21/405) of the control children had
protective antibody levels.
Outcomes
Antibody levels after early vaccination
Antibodylevelsweredeterminedin544childrenaged
9 months who had not had measles infection and had
no known exposure to measles infection at home (see
table on bmj.com). Among children in the treatment
group, 92% (128/139) had a measurable haemaggluti-
nationinhibitionantibodytitrecomparedwith9%(38/
405) among the control children (relative risk 9.81,
95% confidence interval 7.2 to 13.3); 77% (107/139)
and 5% (21/405), respectively, had protective levels
(14.9, 9.7 to 22.7).
Diagnosis of measles infection
Overall,103childrenwerereportedashavingmeasles
between enrolment and within three weeks of measles
vaccinationat9monthsofage.Sevenchildrenhadone
or two negative convalescent samples and were
invalidated. Therefore 96 children had a diagnosis of
measles on the basis of clinical or serological data; 48
(50%) were seen in the acute phase and considered to
have definite clinical measles and the remaining 48
were classified as having probable measles. Sixty nine
children(72%) were serologically confirmed ashaving
definite measles, with a fourfold increase in antibody
levels or a positive response with the IgM test. Of the
remaining 27 children, eight unvaccinated children
hadhighIgGantibodylevelsbutweresampledtoolate
to be IgM positive and no adequate sample was
collected from 19 children, mainly because the child
had died, was admitted to hospital, had travelled, or
was seen only after the measles vaccination at age
9 months when it would be impossible to assess
whether antibodies were due to measles infection or
to vaccination. Eight of the children with no adequate
blood sample had been considered to have clinically
definite measles. Hence, 77 children (80%) had a
serologically confirmed diagnosis or a clinically
definite diagnosis.
Incidence of measles infection
The incidence of measles was high; 4.2% (58/1391) of
the children had measles before enrolment at 4.
5 months; 33 had serologically confirmed measles.
These children were excluded from further analysis
(fig 1). Among the children in the control group 86
contracted measles (fig 2). The monthly incidence was
3.1% (95% confidence interval 2.5% to 3.8%) and for
children remaining unvaccinated the cumulative
incidence reached 14.4% (11.7% to 17.7%) before
9 months of age and 19.4% (14.1% to 26.4%) before
12 months of age. Ten children in the treatment arm
contracted measles (fig 2). The monthly incidence was
0.7% (0.4% to 1.3%) and the cumulative incidence was
3.1% (1.5% to 6.2%) before 9 months of age and 6.7%
(2.6% to 16.4%) before 12 months of age. The case
fatality for all cases was 8.3% (8/96).
Vaccine efficacy
Eleven children had measles within 21 days of
enrolmentandastheymighthavebeeninfectedbefore
enrolment these children were excluded from the
analysis (fig 1). Table 2 shows vaccine efficacy for the
remaining 85 children for those with serologically
confirmed measles, those admitted to hospital for
measles, and for measles mortality. The vaccine
efficacy for serologically confirmed cases was 94%
(74% to 98%) and for clinically definite cases was 91%
(62% to 98%). When serologically confirmed and
clinically definite cases were combined vaccine effi-
cacy was 94% (77% to 99%). Efficacy was as good for
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Fig 2 | Cumulative incidence of measles in children receiving
early immunisation against measles using Edmonston-Zagreb
vaccine at age 4.5 months (treatment) and Schwarz vaccine or
Edmonston-Zagreb vaccine at age 9 months (controls). Of 86
childrenwhocontractedmeaslesinthecontrolgrouptwowere
among infants aged 4 months, 12 aged 5 months, 17 aged
6 months, 28 aged 7 months, 21 aged 8 months, five aged
9months,andoneaged11months.Of10childrenwithmeasles
inthe treatmentgroup twocases occurredamonginfantsaged
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5 or 6 months of age (data not shown). The number
needed to treat to prevent one child having measles
between 4.5 and 9 months of age in an epidemic
situation was 7.2 (95% confidence interval 6.8 to 9.2).
All admissions to hospital for measles occurred
among children in the control arm; vaccine efficacy
against admission was 100% (46% to 100%; table 2).
Apart from admissions for measles, 21 children in the
control arm and eight in the treatment arm were
admitted. Therefore the treatment group had no more
admissions to hospital for non-measles related reasons
than the control group.
The seven deaths from measles that occurred more
than 21 days after enrolment were in the control arm;
vaccine efficacy against death was 100% (−42% to
100%). From the start of the trial to the end of the
measles outbreak, overall mortality was lower in the
treatmentarm(fig1)althoughthemortalityrateratioof
0.18(0.02to1.36)wasnotstatisticallysignificant.Apart
fromthesevendeathsfrommeasles(table 2,fivemore
children in the control groups died with a diagnosis of
measles(hadmeasleswithinthefirst21days),sepsis,or
respiratory tract infection, and two died from severe
malaria.Onechildinthetreatmentarmdiedasaresult
of diarrhoea and vomiting. Therefore the treatment
grouphadnomorenon-measlesrelateddeathsthanthe
control group.
These estimates were not materially changed by
inclusion of children who contracted measles in the
21 days after enrolment or among children who had
beenenrolledtoosoonafterthethreedosevaccination
scheduleagainstdiphtheria,tetanus,andpertussis.The
vaccine efficacy for confirmed cases was 92% (74% to
97%), against admission to hospital was 100% (45% to
100%), and against death was 100% (−7% to 100%;
P=0.034).
DISCUSSION
StandardtitreEdmonston-Zagrebmeaslesvaccination
at 4.5 months of age in Guinea-Bissau was protective
against measles infection and admissionto hospital for
measles.Forchildrenwithdefinitemeasles,protection
was more than 90%. Most of the cases were serologi-
cally verified and, even if we included all self reported
cases,vaccineefficacywasstill80%.Thestudywastoo
small to document significant protection against
measlesmortality.Suchaprotectionis,however,likely
as admission to hospital is a reliable indicator of the
severity of infection and in the analysis that included
children with measles occurring within 21 days of
enrolment and children who had been enrolled too
soon after the three dose diphtheria, tetanus, and
pertussis schedule, the difference in measles mortality
was also significant. Furthermore, overall mortality
mayhavebeensomewhatlowerinthetreatmentgroup
than control group although this was not statistically
significant.
Strengths and weaknesses
The present analysis is an interim report from a large
randomised trial so conclusions should be interpreted
with caution. It is unlikely that further cases of measles
that may modify the estimate of vaccine efficacy will
occur before the end of the trial. The epidemic raised
herd immunity, and a national measles immunisation
campaign of children aged 6 months to 15 years was
carried out in May 2006. The efficacy of early
Edmonston-Zagreb measles vaccination presumably
depends on the level of maternal antibodies and that
could differ in other populations in low income
countries.
33
The most important limitations of the study may
relate to the lack of blinding of vaccination status
among possible measles cases and to the impossibility
of seeing all children in the acute phase of infection.
Firstly, surveys to identify cases in the community and
the detection of cases at the health centres and the
hospital were carried out without reference to the
vaccination status. Although the project doctors were
under instruction not to look at the vaccination card
before diagnosis we cannot be certain they never
looked. Nearly all diagnoses were confirmed in the
independent blinded serological analyses. The selec-
tion of children from whom blood samples were
collected could have been biased. We think this is
unlikely as Guinean doctors have often observed
measles infection in vaccinated children and are
therefore unlikely to be influenced by assumptions
about children vaccinated against measles not getting
the infection. At the paediatric ward, the doctors who
admitted the children would not inspect the vaccina-
tion card and ascertainment at the hospital has been
relativelyblind.Thehospitaldataclearlyshowedgood
protection from Edmonston-Zagreb measles vaccina-
tion at 4.5 months of age. Had an important bias
affected the decision to admit a child with possible
measles to hospital, we should have seen in the treated
group relatively more admissions to hospital for non-
measles related reasons and for deaths not related to
measles.Thatdidnotoccur.Ifanythingfewerchildren
inthetreatedgroupwereadmittedtohospitalfor“non-
Table 2 |Vaccineefficacyagainstmeasles,admissiontohospitalformeasles,andmeasles
mortalitybetweenthreeweeksafterenrolmenttostudyandthreeweeksaftermeaslesvaccination
atage9months,Guinea-Bissau2003-4
Events Treatmentarm* Control arm† Vaccine efficacy (%)
Diagnostic certainty:
All measles cases 8 77 80 (59 to 90)
Serologically confirmed cases 2 60 94 (74 to 98)
Clinically definite cases 2 41 91 (62 to 98)
Serologicallyconfirmedorclinicallydefinitecases 2 66 94 (77 to 99)
Severe measles:
Admission to hospital 0 14 100 (46 to 100)
Measles mortality 0 7 100 (−42 to 100)
Case fatality (deaths/cases) 0/8 7/77
Five of these cases occurred after 9 month vaccination but within 21 days of vaccination: two in Edmonston-
Zagreb vaccine group (4.5 months), and three in control group—one in Schwarz group and two in Edmonston-
Zagreb group (9 months).
*Edmonston-Zagreb measles vaccination at age 4.5 months.
†Measles vaccination using Schwarz vaccine or Edmonston-Zagreb vaccine at age 9 months.
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biasinthediagnosticprocesshashadamajorimpacton
our identification of children with measles.
Secondly, not all children with measles could be
seen, partly because the population is mobile and
infected children may have been absent. More
importantly, the workload during the epidemic made
it impossible for clinicians to search for children with
mild infection who did not turn up for consultation.
Thiscouldhavemeantthatweidentifiedtoofewcases,
particularly children with milder disease. During the
epidemic fieldworkers who were unaware of the
randomisationstatusofthechildrencarriedoutseveral
surveys to identify children with measles. These
surveys identified most of the children with probable
measles. This process provided several opportunities
for mothers to report that their child had had measles.
We therefore think it unlikely that many cases
remained unreported and undetected. The incidence
of measles was high, with 4.2% of the children having
measles before enrolment and an additional 14.4%
before 9 months of age in the control arm.
Critical features of the intervention
We were surprised that vaccine efficacy was so high.
Maternal antibody levels would presumably interfere
withvaccinationat4.5monthsofage.Only28%ofthe
children had protective antibody levels at enrolment,
however, and the Edmonston-Zagreb vaccine may be
able to immunise in the presence of maternal anti
bodies.
101330 Nearly all of the children receiving the
Edmonston-Zagreb vaccine had measurable anti-
bodies at 9 months of age and would be protected or
have had only mild infection.
31 These results apply
only to Edmonston-Zagreb measles vaccine, which
may immunise better in the presence of maternal
antibodies than the Schwarz strain of measles vaccine,
ortheMoratenstrain,whichhasbeenusedwithlimited
success in 6 month old American infants.
34
Changes in the epidemiology of measles infection
Themajoroutbreakofmeaslesoccurredinanareathat
has had intense vaccination activities for many years.
Mobilityishighinthisurbanarea andeven thoughwe
have maintained over 90% coverage
13 many children
moveawayandotherunvaccinatedolderchildrenmay
have moved in. We did try to prevent an outbreak by
recommending more general vaccination in connec-
tion with a vitamin A and missing vaccination
campaign carried out by local health authorities in
November 2003. The international organisations
emphasised that international policy for measles
vaccination was vaccination before 12 months of age
andthatinfantsonlylessthan12monthsofagewereto
receive measles vaccine.
The epidemiology of measles may have changed
fundamentally in recent years. To our knowledge no
study has documented an incidence of 18.6% before
9 months of age in an area with high vaccination
coverage. Measles is still a severe disease. The case
fatality was high despite intensive surveillance, home
visits, and follow-up by doctors, and free treatment at
the hospital. Many low income countries have had a
high coverage for measles vaccination for the past
20 years, since the universal childhood immunisation
activities in the mid-1980s, which reached even the
remotest part of Africa.
35 Increasing numbers of
mothers have been immunised in childhood, and re-
exposuretothevirusmayhavebeenlimited.Therefore
newborn infants will have lower antibody levels and
are likely to become susceptible to measles infection
and responsive to measles vaccination much earlier.
33
This situation is further aggravated by the HIV
epidemic because mothers infected with HIV transmit
lower levels of measles antibodies to their offspring
than uninfected mothers. The low maternal antibody
levels detected in this studyare likely to be representa-
tive of many low income countries. Severe outbreaks
may occur in cities in which surveillance is less intense
and access to care more difficult than in the Bissau
setting.
Policy implications
WHO currently recommends early two dose measles
vaccination at 6 and 9 months of age during measles
outbreaks, in humanitarian emergencies, and in
refugee camps. Immunisation campaigns in response
to outbreaks have often targeted children aged
6 months to 15 years.
3637 Given the strongly beneficial
effectofthevaccinationstrategywetested,itshouldbe
possible to recommend the first dose of Edmonston-
Zagreb measles vaccine at 4.5 months of age in
situations with a high risk of infection before
9 months of age. In situations where control of
outbreaks is needed, the Edmonston-Zagreb vaccine
could be used to immunise young household contacts
who may have some maternal antibodies but not
enoughtopreventthemfrombecominginfectedwhen
exposed at home
15 and to transmit the virus. If
elimination of measles is planned it will be necessary
in Africa to immunise as early as possible for many
years. Several groups are working to produce new
measles vaccines that may provide such early protec-
tion—for example, using BCG or fowlpox as vaccine
carriers. The Edmonston-Zagreb vaccine may also be
useful in this context. Any potential new measles
vaccine used before 6 months of age should be tested
against the Edmonston-Zagreb vaccine, the only
vaccine with proved efficacy in this age range.
In conclusion, we suggest that an early two dose
strategy providing Edmonston-Zagreb vaccination as
early as 4.5 months of age might be used in
humanitarian emergencies or during outbreaks with a
high risk of measles infection. Whether such vaccina-
tion at 4.5 months can be recommended more
generally as the primary measles vaccination in a two
dose strategy might depend on the long term main-
tenanceofprotectivelevels.Wewillcontinuetofollow
thecohortinBissautoassesslongtermmaintenanceof
antibodylevels.Itwouldbeconvenientifthefirstofthe
two dose strategy could be combined with the third
diphtheria, tetanus, and pertussis vaccination. Several
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combination of measles vaccine and diphtheria,
tetanus, and pertussis vaccine has a negative effect on
overall survival.
24-26 Whether these vaccines can be
combined requires testing in a randomised trial. The
strategy with early measles vaccination should be
studied in other sites as well.
Given international financial support, supplemental
immunisation activities are likely to continue in even
the poorest African countries. It might be thought that
measles can be controlled in Africa in the same way it
hasbeen controlledin LatinAmerica and thatan early
two dose strategy is not necessary. Supplemental
immunisation activities are, however, unlikely to
control measles fully,
21 and local outbreaks will
continue to occur. With the changing antibody profile
of mothers in Africa, the high birth rate, and rapid
urbanisation, African cities will be open to major
outbreaksofmeaslesshouldtherebepoliticalupheaval
or financial problems leading to failure to maintain a
high measles vaccination coverage. An early two dose
measles vaccination strategy, if not associated with a
subsequent loss of protection at older ages, could
strengthen the current efforts to control measles and
reducemeaslesmortality.Henceareductionintheage
of routine measles immunisation and possibly a two
dose strategy should be considered.
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